On 30 October 2019 the Chief Pharmaceutical Inspectorate granted a new Manufacturing Authorisation for F1 Pharma S.A.
As a result of the transformation of F1 Pharma into a joint stock company, we submitted a request to the Chief Pharmaceutical Inspectorate for the amendment of our Manufacturing Authorisation.
F1 Pharma successfully completed project granted by the National Center of Research and Development in Fast Track programme fulfilling both scientific and financial targets.
We are happy to inform that the project of “The development of innovative forms of mucolytic drugs, suitable for application to children, elderly persons and persons suffering from esophageal dysphagia”, funded by the National Centre for Research and Development (NCBiR), under the R&D Business Projects scheme, has been completed, accepted and financially concluded with the NCBiR.
On 6 August 2019 the District Court listed F1 Pharma S.A. in the National Court Register of companies under the KRS number: 0000797961.
F1 Pharma S.A. was conceived as a result of the transformation of F1 Pharma Sp. z o. o. pursuant to the resolution of the Shareholders Meeting based in Kraków, on 3 April 2019, on the transformation of F1 Pharma Sp. z o. o. into a joint stock company.